|
業務類別
|
Biotechnology |
|
業務概覽
|
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101. |
| 公司地址
| 400 Alexander Park Drive, Suite 301, Princeton, NJ, USA, 08540 |
| 電話號碼
| +1 609 642-6670 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.pmvpharma.com |
| 員工數量
| 47 |
| Mr. Robert Ticktin |
General Counsel and Chief Operating Officer |
-- |
25/04/2025 |
| Mr. Michael Carulli |
Chief Financial Officer and Principal Accounting Officer |
美元 370.00K |
06/03/2026 |
| Dr. Deepika Jalota, Pharm.D. |
Chief Development Officer |
美元 442.54K |
25/04/2025 |
| Dr. David H. Mack, PhD |
President, Chief Executive Officer and Director |
美元 607.21K |
06/03/2026 |
|
|
| Dr. Charles M. Baum, M.D.,PhD |
Independent Director |
06/03/2026 |
| Ms. Laurie D. Stelzer, M.B.A. |
Independent Director |
06/03/2026 |
| Dr. David H. Mack, PhD |
President, Chief Executive Officer and Director |
06/03/2026 |
| Dr. Carol G. Gallagher,Pharm.D. |
Independent Director |
06/03/2026 |
| Dr. Richard Heyman, PhD |
Chairman of the Board |
06/03/2026 |
| Dr. Arnold J. Levine,PhD |
Independent Director |
06/03/2026 |
| Ms. Kirsten Flowers |
Independent Director |
06/03/2026 |
|
|
|
|
